Page last updated: 2024-10-30

edaravone and Intracranial Arteriosclerosis

edaravone has been researched along with Intracranial Arteriosclerosis in 1 studies

Intracranial Arteriosclerosis: Vascular diseases characterized by thickening and hardening of the walls of ARTERIES inside the SKULL. There are three subtypes: (1) atherosclerosis with fatty deposits in the ARTERIAL INTIMA; (2) Monckeberg's sclerosis with calcium deposits in the media and (3) arteriolosclerosis involving the small caliber arteries. Clinical signs include HEADACHE; CONFUSION; transient blindness (AMAUROSIS FUGAX); speech impairment; and HEMIPARESIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yamamoto, Y1
Ohara, T1
Nagakane, Y1
Tanaka, E1
Morii, F1
Koizumi, T1

Reviews

1 review available for edaravone and Intracranial Arteriosclerosis

ArticleYear
[Concept of branch atheromatous disease (BAD) and its clinical significance].
    Rinsho shinkeigaku = Clinical neurology, 2010, Volume: 50, Issue:11

    Topics: Antipyrine; Arginine; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Edaravone; Humans;

2010